Phase II multicenter pilot study of safety, efficacy, and immune cell profiling in advanced hepatocellular carcinoma (HCC) on combination of sorafenib (SOR) plus nivolumab (NIVO).

被引：4
|
作者：
Keenan, Bridget
Griffith, Madeline J.
Bauer, Kelly
Bracci, Paige M.
Behr, Spencer
Umetsu, Sarah E.
Gordan, John Dozier
Ngo, Zoe
Iqbal, Syma
Hanna, Diana L.
Venook, Alan P.
El-Khoueiry, Anthony B.
Fong, Lawrence
Kelley, Robin Kate
机构：
[1] Univ Calif San Francisco, San Francisco, CA 94143 USA
[2] Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA 94143 USA
[3] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA
[4] Univ Calif San Francisco, Dept Pathol, San Francisco, CA 94140 USA
[5] UCSF Helen Diller Family Comprehens Canc Ctr, San Francisco, CA USA
[6] USC Norris Comprehens Canc Ctr, Keck Sch Med, Div Med Oncol, Los Angeles, CA USA
[7] Univ Southern Calif, Norris Comprehens Canc Ctr, Los Angeles, CA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 37卷 / 04期
关键词：
D O I：
10.1200/JCO.2019.37.4_suppl.TPS464
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS464
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Phase Ib study of codrituzumab in combination with sorafenib in patients with non-curable advanced hepatocellular carcinoma (HCC)
    Ghassan K. Abou-Alfa
    Chia-Jui Yen
    Chih-Hung Hsu
    Joseph O’Donoghue
    Volkan Beylergil
    Shutian Ruan
    Neeta Pandit-Taskar
    Bolorsukh Gansukh
    Serge K. Lyashchenko
    Jennifer Ma
    Peter Wan
    Yu-Yun Shao
    Zhong-Zhe Lin
    Catherine Frenette
    Bert O’Neil
    Lawrence Schwartz
    Peter M. Smith-Jones
    Toshihiko Ohtomo
    Takayoshi Tanaka
    Hideo Morikawa
    Yuko Maki
    Norihisa Ohishi
    Ya-Chi Chen
    Tamara Agajanov
    Frederic Boisserie
    Laura Di Laurenzio
    Ray Lee
    Steven M. Larson
    Ann-Lii Cheng
    Jorge A. Carrasquilo
    Cancer Chemotherapy and Pharmacology, 2017, 79 : 421 - 429
  • [42] Phase Ib study of codrituzumab in combination with sorafenib in patients with non-curable advanced hepatocellular carcinoma (HCC)
    Abou-Alfa, Ghassan K.
    Yen, Chia-Jui
    Hsu, Chih-Hung
    O'Donoghue, Joseph
    Beylergil, Volkan
    Ruan, Shutian
    Pandit-Taskar, Neeta
    Gansukh, Bolorsukh
    Lyashchenko, Serge K.
    Ma, Jennifer
    Wan, Peter
    Shao, Yu-Yun
    Lin, Zhong-Zhe
    Frenette, Catherine
    O'Neil, Bert
    Schwartz, Lawrence
    Smith-Jones, Peter M.
    Ohtomo, Toshihiko
    Tanaka, Takayoshi
    Morikawa, Hideo
    Maki, Yuko
    Ohishi, Norihisa
    Chen, Ya-Chi
    Agajanov, Tamara
    Boisserie, Frederic
    Di Laurenzio, Laura
    Lee, Ray
    Larson, Steven M.
    Cheng, Ann-Lii
    Carrasquilo, Jorge A.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2017, 79 (02) : 421 - 429
  • [43] Gemcitabine plus oxallplatin (GEMOX) in advanced hepatocellular carcinoma (HCC): results of a phase II study
    Mansourbakht, T.
    Boige, V.
    Louafi, S.
    Bonyhay, L.
    De Baere, T.
    Ducreux, M.
    Poynard, T.
    Taieb, J.
    EJC SUPPLEMENTS, 2005, 3 (02): : 215 - 215
  • [44] Phase III randomized study of sorafenib plus doxorubicin versus sorafenib in patients with advanced hepatocellular carcinoma (HCC): CALGB 80802 (Alliance).
    Abou-Alfa, Ghassan K.
    Niedzwieski, Donna
    Knox, Jennifer J.
    Kaubisch, Andreas
    Posey, James
    Tan, Benjamin R.
    Kavan, Petr
    Goel, Rakesh
    Murray, John J.
    Bekaii-Saab, Tanios S.
    Tam, Vincent Channing
    Rajdev, Lakshmi
    Kelley, Robin Kate
    Siegel, Abby
    Balletti, Jennifer
    Harding, James J.
    Schwartz, Lawrence Howard
    Goldberg, Richard M.
    Bertagnolli, Monica M.
    Venook, Alan P.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (04)
  • [45] Phase III randomized study of sorafenib plus doxorubicin versus sorafenib in patients with advanced hepatocellular carcinoma (HCC): CALGB 80802 (Alliance)
    Abou-Alfa, Ghassan K.
    Niedzwieski, Donna
    Knox, Jennifer J.
    Kaubisch, Andreas
    Posey, James
    Tan, Benjamin R.
    Kavan, Petr
    Goel, Rakesh
    Lammers, Philip Edward
    Bekaii-Saab, Tanios S.
    Tam, Vincent Channing
    Rajdev, Lakshmi
    Kelley, Robin Kate
    Siegel, Abby B.
    Balletti, Jennifer
    Harding, James J.
    Howard, Lawrence Schwartz
    Goldberg, Richard M.
    Bertagnolli, Monica M.
    Venook, Alan P.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [46] Combination of capecitabine, oxaliplatin with bevacizumab in treatment of advanced hepatocellular carcinoma (HCC): A phase II study
    Sun, W.
    Haller, D. G.
    Mykulowycz, K.
    Rosen, M.
    Soulen, M.
    Capparo, M.
    Faust, T.
    Giantonia, B.
    Olthoff, K.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [47] Phase Ib trial of selinexor (SEL) in combination with nivolumab (NIVO) alone or nivolumab plus ipilimumab (NIVO plus IPI) in patients (pts) with advanced malignancies: The renal cell carcinoma (RCC) experience.
    Alhalabi, Omar
    Tannir, Nizar M.
    Momin, Hassan Ahmed
    Yilmaz, Bulent
    Stephen, Bettzy
    Ejezie, Chinenye Lynette
    Moyers, Justin Tyler
    Gurses, Serdar A.
    How, Jeffrey
    Fu, Siqing
    Ahnert, Jordi Rodon
    Hong, David S.
    Piha-Paul, Sarina Anne
    Subbiah, Vivek
    Dumbrava, Ecaterina Elena
    Karp, Daniel D.
    Janku, Filip
    Meric-Bernstam, Funda
    Naing, Aung
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [48] Phase I/II study of E7050 (golvantinib) in combination with sorafenib in patients (pts) with advanced hepatocellular carcinoma (HCC): Phase I results
    O'Neil, Bert H.
    Bendell, Johanna C.
    Modiano, Manuel R.
    Machiels, Jean-Pascal H.
    Versola, Melissa Jo
    Hodge, Jeff Paul
    Sawarna, Karen
    Tse, Nielson
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (04)
  • [49] CHECKMATE 040: EFFICACY, HEPATIC SAFETY, AND BIOMARKERS OF NIVOLUMAB plus IPILIMUMAB COMBINATION THERAPY IN PATIENTS WITH ADVANCED HEPATOCELLULAR CARCINOMA
    Sangro, Bruno
    Hsu, Chiun
    Kang, Yoon-Koo
    Kim, Tae-You
    El-Khoueiry, Anthony
    Santoro, Armando
    Melero, Ignacio
    Kudo, Masatoshi
    Hou, Ming-Mo
    Pena, Ana Matilla
    Tovoli, Francesco
    Knox, Jennifer J.
    He, Aiwu Ruth
    El-Rayes, Bassel
    Acosta, Mirelis Rivera
    Lim, Ho-Yeong
    Neely, Jaclyn
    Zhao, Huanyu
    Anderson, Jeffrey
    Yau, Thomas
    HEPATOLOGY, 2019, 70 : 131A - 132A
  • [50] BBI608-503-103HCC: A phase Ib/II clinical study of napabucasin (BBI608) in combination with sorafenib or amcasertib (BBI503) in combination with sorafenib (Sor) in adult patients with hepatocellular carcinoma (HCC).
    El-Rayes, Bassel F.
    Richards, Donald A.
    Cohn, Allen Lee
    Richey, Stephen Lane
    Feinstein, Trevor
    Kundranda, Madappa N.
    El-Khoueiry, Anthony B.
    Melear, Jason M.
    Braiteh, Fadi S.
    Hitron, Matthew
    Ortuzar, Waldo Feliu
    Khan, Waheed
    Xu, Bo
    Li, Wei
    Li, Youzhi
    Li, C. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
12345